Panacur Equine Granules 22.2% w/w

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Buy It Now

Active ingredient:

Fenbendazole

Available from:

MSD Animal Health UK Limited

ATC code:

QP52AC13

INN (International Name):

Fenbendazole

Pharmaceutical form:

Granules

Prescription type:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Therapeutic group:

Horses

Therapeutic area:

Anthelmintic

Authorization status:

Authorized

Authorization date:

1993-01-29

Summary of Product characteristics

                                Revised: December 2020
AN: 01394/2020
Page 1 of 5
SUMMARY
OF
PRODUCT
CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Panacur Equine Granules 22.2% w/w
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES
Qualitative composition
Quantitiative composition % w/w
Fenbendazole
22.222
Excipients
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Granules
A white to yellowish-white granular powder.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and other equines.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A broad spectrum anthelmintic for the treatment and control of adult
and
immature roundworms of the gastro-intestinal tract in horses and other
equines.
Panacur effectively treats and controls the following roundworm
infections:
Large strongyles (adults and migrating larval stages of _S.vulgaris_;
adults and tissue
larval stages of _S. edentatus_)
Adult and immature small strongyles (Cyathostomes) (benzimidazole
susceptible)
including encysted mucosal 3rd and 4th stage larvae; it is also
effective against
inhibited 3rd stage larvae (encysted) in the mucosa.
Adult and immature _Oxyuris spp., Strongyloides spp._ and _Parascaris
equorum._
Panacur also has an ovicidal effect on nematode eggs.
4.3
CONTRA-INDICATIONS
None known.
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk
of development of resistance and could ultimately result in
ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an
extended period of time.
•
Under dosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosing
device (if
any).
Revised: December 2020
AN: 01394/2020
Page 2 of 5
Suspected clinical cases of resistance to anthelmintics should be
further investigated
using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where
the results of
the test(s) strongly suggest resistance to a particular anthelm
                                
                                Read the complete document
                                
                            

Search alerts related to this product